Pharmalink AB completes fundraising

Pharmalink reports positive phase III results for Xepol®, a treatment for postpolio syndrome

Pharmalink reports the approval of key patent for chemotherapy drug BusulipoTM

Pharmalink reports promising interim results from phase II trials for new renal disease drug Nefecon®